CLINICAL_TRIALS
trial_result
· 2017-05-09
Clinical Trial Update: A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122) [Phase 3]
Summary
A Phase 3 trial evaluating the effect of rofecoxib (MK0966) on the recurrence of colorectal adenomas; the study is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Adenoma | Phase 3 | Status: COMPLETED